Predicting response to immunotherapy in gastric cancer via multi-dimensional analyses of the tumour immune microenvironment.
Predicting response to immunotherapy in gastric cancer via multi-dimensional analyses of the tumour immune microenvironment.
复制标题
DOI：
10.1038/s41467-022-32570-z
复制
发表时间：
2022-08-18
影响因子：
16.6
通讯作者：
中科院分区：
文献类型：
--
作者：
单一生物标志物不足以识别有可能从抗 PD-1/PD-L1 治疗中获益的胃癌 (GC) 患者，这可能是由于肿瘤微环境的复杂性。肿瘤浸润免疫细胞（TIIC）的密度和空间组织的预测价值尚未明确确定。在这里，使用多重免疫组织化学以亚细胞分辨率对 80 名 GC 患者的原位生物标志物进行定量。为了预测对免疫治疗的反应，我们通过考虑 CD4+FoxP3−PD-L1+、CD8+PD-1−LAG3− 和 CD68+STING+ 细胞的密度以及 CD8+PD-1+LAG3− T 细胞的空间组织来建立多维 TIIC 特征。 TIIC 特征能够预测 GC 患者对抗 PD-1/PD-L1 免疫疗法的反应和患者生存率。我们的研究结果表明，多维 TIIC 特征可能与选择能够从抗 PD-1/PD-L1 免疫疗法中获益最多的患者相关。需要针对胃癌的预测方法来尝试和区分潜在的治疗反应。在这里，作者使用多重免疫组织化学方法提出肿瘤浸润免疫细胞的接近程度作为可能的治疗反应的指标。
A single biomarker is not adequate to identify patients with gastric cancer (GC) who have the potential to benefit from anti-PD-1/PD-L1 therapy, presumably owing to the complexity of the tumour microenvironment. The predictive value of tumour-infiltrating immune cells (TIICs) has not been definitively established with regard to their density and spatial organisation. Here, multiplex immunohistochemistry is used to quantify in situ biomarkers at sub-cellular resolution in 80 patients with GC. To predict the response to immunotherapy, we establish a multi-dimensional TIIC signature by considering the density of CD4+FoxP3−PD-L1+, CD8+PD-1−LAG3−, and CD68+STING+ cells and the spatial organisation of CD8+PD-1+LAG3− T cells. The TIIC signature enables prediction of the response of patients with GC to anti-PD-1/PD-L1 immunotherapy and patient survival. Our findings demonstrate that a multi-dimensional TIIC signature may be relevant for the selection of patients who could benefit the most from anti-PD-1/PD-L1 immunotherapy. Predictive methods for gastric cancer to try and differentiate between potential treatment response are required. Here the authors use a multiplexed immunohistochemistry method to propose the proximity of tumour infiltrating immune cells as an indicator of likely therapeutic response.
登录
查看更多内容
DOI：
10.1016/s1470-2045(20)30169-8
发表时间：
2020-06
期刊：
The Lancet. Oncology
影响因子：
--
作者：
Janjigian YY;Maron SB;Chatila WK;Millang B;Chavan SS;Alterman C;Chou JF;Segal MF;Simmons MZ;Momtaz P;Shcherba M;Ku GY;Zervoudakis A;Won ES;Kelsen DP;Ilson DH;Nagy RJ;Lanman RB;Ptashkin RN;Donoghue MTA;Capanu M;Taylor BS;Solit DB;Schultz N;Hechtman JF
通讯作者：
Hechtman JF
影响因子：
7.2
作者：
Machiraju D;Wiecken M;Lang N;Hülsmeyer I;Roth J;Schank TE;Eurich R;Halama N;Enk A;Hassel JC
通讯作者：
Hassel JC
影响因子：
4.4
作者：
Fujiyoshi, Kenji;Chen, Yang;Ogino, Shuji
通讯作者：
Ogino, Shuji
影响因子：
5.8
作者：
Di Bartolomeo, Maria;Morano, Federica;Cavanna, Luigi
通讯作者：
Cavanna, Luigi
影响因子：
16.6
作者：
Huang, Yu-Kuan;Wang, Minyu;Boussioutas, Alex
通讯作者：
Boussioutas, Alex